Celestia Higano

Celestia Higano

UNVERIFIED PROFILE

Are you Celestia Higano?   Register this Author

Register author
Celestia Higano

Celestia Higano

Publications by authors named "Celestia Higano"

Are you Celestia Higano?   Register this Author

100Publications

3793Reads

21Profile Views

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

Eur Urol 2019 Sep 19;76(3):306-312. Epub 2018 Nov 19.

Chris O'Brien Lifehouse, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; University of NSW, Sydney, Australia; University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.11.001DOI Listing
September 2019

Back to Basics: Addressing Bone Health in Men with Prostate Cancer on Androgen Deprivation Therapy.

Eur Urol Oncol 2019 Sep 1;2(5):562-564. Epub 2019 Aug 1.

Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.07.004DOI Listing
September 2019

Correction to: Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors.

Support Care Cancer 2019 Jul 16. Epub 2019 Jul 16.

Vancouver Prostate Centre, 2660 Oak St, Vancouver, BC, V6H 3Z6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04986-9DOI Listing
July 2019

Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

Authors:
Celestia Higano

Nat Rev Urol 2019 Jun;16(6):335-336

Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0186-2DOI Listing
June 2019

Prostate Cancer National Summit's Call to Action.

Clin Genitourin Cancer 2019 Jun 16;17(3):161-168. Epub 2019 Apr 16.

Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.04.002DOI Listing
June 2019

Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors.

Support Care Cancer 2019 Jun 25. Epub 2019 Jun 25.

Vancouver Prostate Centre, 2660 Oak St, Vancouver, BC, V6H 3Z6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04927-6DOI Listing
June 2019

Germline and Somatic Mutations in Prostate Cancer for the Clinician.

J Natl Compr Canc Netw 2019 May;17(5):515-521

aDivision of Medical Oncology, University of Washington, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.7307DOI Listing
May 2019

A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.

Leuk Lymphoma 2019 Apr 24:1-8. Epub 2019 Apr 24.

a Department of Medicine Division of Oncology , University of Washington , Seattle , WA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1605508DOI Listing
April 2019

Impact of androgen deprivation therapy on mood, cognition, and risk for AD.

Urol Oncol 2019 Mar 9. Epub 2019 Mar 9.

Departments of Psychiatry and Behavioral Sciences and Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.01.021DOI Listing
March 2019

Introduction to the seminar series: Optimal management during ADT to mitigate complications.

Urol Oncol 2018 Dec 7. Epub 2018 Dec 7.

Department of Medicine, University of Washington, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.10.022DOI Listing
December 2018

Editorial Comment.

J Urol 2018 11 24;200(5):1081. Epub 2018 Jul 24.

Department of Urology, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00225347184354
Publisher Site
http://dx.doi.org/10.1016/j.juro.2018.04.105DOI Listing
November 2018

Does nonmetastatic castration-resistant prostate cancer still exist?

Nat Rev Clin Oncol 2018 06;15(6):350-351

Division of Medical Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0025-z
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0025-zDOI Listing
June 2018

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Am Soc Clin Oncol Educ Book 2018 May;38:363-371

From the Division of Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; Division of Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, University of California-San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200967
Publisher Site
http://dx.doi.org/10.1200/EDBK_200967DOI Listing
May 2018

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.

Sci Rep 2018 02 8;8(1):2673. Epub 2018 Feb 8.

Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8505, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-20788-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805696PMC
February 2018

Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.

BJU Int 2017 11 17;120(5B):E21-E29. Epub 2017 May 17.

Vancouver Prostate Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver General Hospital, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.13885DOI Listing
November 2017

The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer.

J Urol 2017 05 21;197(5):1184-1186. Epub 2017 Feb 21.

Departments of Medicine and Urology, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00225347173028
Publisher Site
http://dx.doi.org/10.1016/j.juro.2017.02.065DOI Listing
May 2017

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Ther Adv Med Oncol 2017 May 22;9(5):319-333. Epub 2017 Mar 22.

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017698644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424866PMC
May 2017

Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.

Clin Genitourin Cancer 2017 04 18;15(2):273-279.e1. Epub 2016 Oct 18.

Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.10.002DOI Listing
April 2017

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.

Anticancer Drugs 2017 01;28(1):120-126

aSchool of Medicine bDepartment of Cell, Developmental and Cancer Biology cKnight Cancer Institute, Oregon Health and Science University Departments of dUrology and Radiation Medicine eSpecialty Medicine, VA Portland Health Care System, Portland, Oregon Departments of fImmunology gBreast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida Departments of hMedicine iUrology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000438DOI Listing
January 2017

Reply to M.A.N. Şendur et al and J. Michels.

J Clin Oncol 2017 01 31;35(1):123. Epub 2016 Oct 31.

David F. Penson, Vanderbilt University and the VA Tennessee Valley Geriatric Research, Education, and Clinical Center, Nashville, TN; Andrew J. Armstrong, Duke University, Durham, NC; Raoul Concepcion, Urology Associates PC, Nashville, TN; Neeraj Agarwal, University of Utah, Salt Lake City, UT; Carl Olsson, Icahn School of Medicine at Mount Sinai, New York, NY; Lawrence Karsh, The Urology Center of Colorado, Denver, CO; Curtis Dunshee, Urological Associates of Southern Arizona, Tucson, AZ; Fong Wang and Kenneth Wu, Medivation, San Francisco, CA; Andrew Krivoshik, Astellas Pharma Global Development, Northbrook, IL; De Phung, Astellas Pharma Global Development, Leiden, Netherlands; and Celestia S. Higano, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.9371DOI Listing
January 2017

Intermittent Androgen Deprivation Therapy-An Important Treatment Option for Prostate Cancer.

JAMA Oncol 2016 Dec;2(12):1531-1532

Division of Medical Oncology, Departments of Medicine and Urology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3138DOI Listing
December 2016

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.

Cancer 2016 Aug 18;122(16):2524-33. Epub 2016 May 18.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30073DOI Listing
August 2016

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

J Clin Oncol 2016 06 25;34(18):2098-106. Epub 2016 Jan 25.

David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Administration Medical Center Geriatric Research, Education, and Clinical Center; Raoul Concepcion, Urology Associates PC, Nashville, TN; Andrew J. Armstrong, Duke Cancer Institute, Duke University, Durham, NC; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Carl Olsson, Icahn School of Medicine at Mount Sinai, New York, NY; Lawrence Karsh, The Urology Center of Colorado, Denver, CO; Curtis Dunshee, Urological Associates of Southern Arizona, Tucson, AZ; Fong Wang and Kenneth Wu, Medivation, San Francisco, CA; Andrew Krivoshik, Astellas Pharma Global Development, Northbrook, IL; De Phung, Astellas Pharma Global Development, Leiden, The Netherlands; and Celestia S. Higano, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.9285DOI Listing
June 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Sexual Health After Cancer Therapy.

J Oncol Pract 2016 Apr;12(4):305-6

University of Washington, Seattle, WA; University of British Columbia; and Vancouver Prostate Centre, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.011536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015453PMC
April 2016

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy.

PLoS One 2015 24;10(6):e0130372. Epub 2015 Jun 24.

Institute of Industrial Science, The University of Tokyo, Meguro-ku, Tokyo 153-8505, Japan; Graduate School of Information Science and Technology, The University of Tokyo, Tokyo, Japan; Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0130372PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481271PMC
March 2016

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

J Clin Oncol 2016 Jan 9;34(3):280-5. Epub 2015 Nov 9.

Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Catherine Tangen, SWOG Statistical Center; Celestia Higano, University of Washington, Seattle, WA; Nicholas Vogelzang, US Oncology, Las Vegas, NV; and Ian Thompson, University of Texas Health Science Center, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.8065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242560PMC
January 2016

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

PLoS One 2014 30;9(10):e111545. Epub 2014 Oct 30.

Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0111545PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214744PMC
December 2015

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

J Urol 2015 Dec 18;194(6):1537-47. Epub 2015 Jul 18.

Smilow Cancer Center, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.06.106DOI Listing
December 2015

Mapping the course after CHAARTED.

Nat Rev Urol 2015 Dec 3;12(12):656-8. Epub 2015 Nov 3.

Departments of Medicine and Urology, University of Washington, 825 Eastlake Avenue East, Seattle, WA 98109-1023, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrurol.2015.255
Publisher Site
http://dx.doi.org/10.1038/nrurol.2015.255DOI Listing
December 2015

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Can J Urol 2015 Dec;22(6):8048-55

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
December 2015

Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

PLoS One 2014 8;9(9):e104271. Epub 2014 Sep 8.

Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Pathology, University of Washington, Seattle, Washington, United States of America; Department of Urology, University of Washington, Seattle, Washington, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0104271PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157741PMC
November 2015

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Eur Urol 2015 Nov 16;68(5):795-801. Epub 2015 Feb 16.

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.01.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013546PMC
November 2015

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol 2015 May 6;33(14):1601-8. Epub 2015 Apr 6.

Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417730PMC
May 2015

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

J Clin Oncol 2015 Apr 26;33(12):1356-63. Epub 2015 Jan 26.

Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.3875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881370PMC
April 2015

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

J Clin Oncol 2015 Apr 2;33(10):1151-6. Epub 2015 Mar 2.

Laurence Klotz, Sunnybrook Health Sciences Centre, University of Toronto; Mary Gospodarowicz, Princess Margaret Hospital, Toronto; Chris O'Callaghan and Keyue Ding, Queen's University, Kingston; Shawn Malone, Ottawa Regional Cancer Centre, Ottawa, Ontario; Paul Toren, Larry Goldenberg, and Juanita M. Crook, University of British Columbia, Vancouver, British Columbia, Canada; David Dearnaley, Royal Marsden Hospital, London, United Kingdom; Celestia S. Higano, Fox Chase Cancer Center, Philadelphia, PA; and Eric Horwitz, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.2973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372851PMC
April 2015

Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.

J Clin Endocrinol Metab 2014 Oct 27;99(10):E1967-75. Epub 2014 Jun 27.

Department of Medical Sciences (D.P.) and Biostatistics (E.R.), Amgen Inc (D.P.), Thousand Oaks, California 91320; Department of Medicine (C.S.H.), University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98109; Carolina Urologic Research Center, (N.D.S.), Myrtle Beach, South Carolina 29579; Urological Associates of Lancaster (P.S.), Lancaster, Pennsylvania 17604; and Massachusetts General Hospital Cancer Center (M.R.S.), Boston, Massachusetts 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2014-1271DOI Listing
October 2014

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

J Clin Oncol 2014 Oct 15;32(30):3391-9. Epub 2014 Sep 15.

Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/09/15/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.5954
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.5954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383838PMC
October 2014

Quantitative and stoichiometric analysis of the microRNA content of exosomes.

Proc Natl Acad Sci U S A 2014 Oct 29;111(41):14888-93. Epub 2014 Sep 29.

Divisions of Human Biology, Departments of Internal Medicine and Clinical Research, Biomedical Engineering, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; Biointerfaces Institute, and Center for Computational Medicine, University of Michigan, Ann Arbor, MI 48109; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1408301111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205618PMC
October 2014

Intermittent versus continuous androgen deprivation therapy.

J Natl Compr Canc Netw 2014 May;12(5):727-33

From the University of Washington, Seattle Cancer Care Alliance, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0074DOI Listing
May 2014

New developments in the treatment of castration-resistant prostate cancer.

J Natl Compr Canc Netw 2014 May;12(5 Suppl):773-6

Presented by Celestia S. Higano, MD, Professor, Departments of Medicine and Urology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0187DOI Listing
May 2014

To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.

J Clin Oncol 2014 Apr 3;32(11):1107-11. Epub 2014 Mar 3.

University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.53.8900
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.53.8900DOI Listing
April 2014

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

J Clin Oncol 2014 Apr 10;32(11):1136-42. Epub 2014 Mar 10.

Amir Goldkorn, David I. Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles; Przemyslaw Twardowski, City of Hope, Duarte; Philip C. Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA; Benjamin Ely and Catherine M. Tangen, Southwest Oncology Group Statistical Center; Celestia S. Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA; Louis M. Fink, Nevada Cancer Institute; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV; Peter J. Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Michael A. Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD; J. Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH; Ram H. Datar and Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL; Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, OR; Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Ian Murchie Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.7417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970171PMC
April 2014

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Clin Cancer Res 2014 Mar 18;20(5):1306-12. Epub 2013 Dec 18.

Authors' Affiliations: Knight Cancer Institute; Department of Public Health and Preventive Medicine; Knight Diagnostic Laboratories, Oregon Health and Science University; Portland VA Medical Center, Portland, Oregon; and Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947466PMC
March 2014

Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

Expert Rev Anticancer Ther 2014 Jan;14(1):51-61

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://search.proquest.com/openview/a3792b8afdb6152d2ddbeabd
Web Search
http://www.tandfonline.com/doi/full/10.1586/14737140.2014.84
Publisher Site
http://dx.doi.org/10.1586/14737140.2014.848065DOI Listing
January 2014

Prostate cancer, version 1.2014.

J Natl Compr Canc Netw 2013 Dec;11(12):1471-9

From 1Roswell Park Cancer Institute; 2Dana-Farber/Brigham and Women's Cancer Center; 3Duke Cancer Institute; 4The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 5Huntsman Cancer Institute at the University of Utah; 6Memorial Sloan-Kettering Cancer Center; 7Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 8Prostate Health Education Network; 9University of Washington/Seattle Cancer Care Alliance; 10Fox Chase Cancer Center; 11City of Hope Comprehensive Cancer Center; 12Massachusetts General Hospital Cancer Center; 13Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 14Vanderbilt-Ingram Cancer Center; 15University of Michigan Comprehensive Cancer Center; 16Moffitt Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20Patient Advocate; 21Stanford Cancer Institute; 22Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 24National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0174DOI Listing
December 2013

Urological cancer: α-emitting radium-223-additional choices, more unknowns.

Authors:
Celestia Higano

Nat Rev Clin Oncol 2013 Nov 10;10(11):612-3. Epub 2013 Sep 10.

University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4-830, Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.168DOI Listing
November 2013